Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
- PMID: 31748873
- PMCID: PMC7229099
- DOI: 10.1007/s40120-019-00170-7
Knowledge Is Power, but Is Ignorance Bliss? Optimising Conversations About Disease Progression in Multiple Sclerosis
Abstract
Communication about multiple sclerosis (MS) disease progression between healthcare professionals (HCPs) and people with MS (PwMS) has historically been considered difficult, and attention to improving it has been neglected. However, a growing number of studies have shown that this is a key area to get right, since negative experiences can affect patient satisfaction, treatment adherence, and clinical outcomes. This article reports on a symposium at the European Charcot Foundation, 2018, led by a panel of leading clinicians and patient experts from MS in the 21st Century, who debated the benefits, drawbacks, and challenges of communicating about disease progression, for both HCPs and PwMS, and potential ways to optimise these discussions. PwMS' preferences and priorities regarding conversations about disease progression vary widely. While the majority want to have these conversations, some will be reluctant and/or emotionally unready. Communication therefore needs to be personalised, and HCPs should always be prepared to have such conversations in an appropriate and sensitive manner. Clinical information can be opaque for PwMS, so HCPs also need to use language that is clear, easily understandable, and patient-friendly. MS in the 21st Century is in the process of developing several resources and programmes to help improve disease progression communication between HCPs and PwMS. FUNDING: Merck KGaA, Darmstadt, Germany. Plain language summary available for this article.
Keywords: Communication; Disease progression; MS in the 21st Century; Multiple sclerosis; Patient engagement.
Conflict of interest statement
Patrick Vermersch receives honoraria and consulting fees from Biogen, Sanofi Genzyme, Bayer, Novartis, Teva, Merck, Celgene and Almirall, and research support from Biogen, Sanofi Genzyme, Bayer and Merck. Jane Shanahan receives honoraria from Merck KGaA as part of her work on MS in the 21st Century. Dawn Langdon has participated in speakers’ bureaus for Bayer, Merck, Almirall, Excemed, Teva, Roche, Novartis, Biogen, and Sanofi; has received consultancy honoraria from Novartis, Bayer, Merck, Biogen, Teva, and Sanofi; and has received research grants from Bayer, Merck, Novartis, and Biogen, all paid to her institution. Dawn Langdon is also a member of this journal’s Editorial board. David Yeandle receives honoraria from Merck KGaA as part of his work on MS in the 21st Century. Nektaria Alexandri is an employee of Merck KGaA. Sven Schippling receives consulting and speaker fees and travel grants from Biogen Idec, Bayer, Merck, Sanofi Genzyme/Sanofi Aventis, Novartis, Teva, and research grants from Bayer, Biogen Idec, Merck Serono, Sanofi Genzyme/Sanofi Aventis, Novartis.
References
-
- Kourakos M. Communication as the basis of care for patients with chronic diseases. Am J Nurs Sci. 2017;7:7–12.
LinkOut - more resources
Full Text Sources
